Press Releases :: Sutro Biopharma, Inc. (STRO)

Oct 12, 2018 7:00 am EDT

Sutro's STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma

Sep 26, 2018 6:58 pm EDT

Sutro Biopharma Announces $85.0 Million Initial Public Offering

Sep 12, 2018 8:00 am EDT

Sutro Taps Worsley as Chief Business Officer; Names Fitzpatrick as People and Communications Chief

Aug 13, 2018 8:00 am EDT

Sutro and The Leukemia & Lymphoma Society Partner on Lymphoma and Multiple Myeloma Treatment

Jul 26, 2018 10:45 am EDT

Sutro Biopharma Announces $85.4 Million Series E Round

Jul 24, 2018 8:00 am EDT

Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders

Apr 26, 2018 8:00 am EDT

Sutro Initiates First Clinical Trial of CD74-Targeting ADC for Lymphoma & Multiple Myeloma Treatment; The First of a New Generation of Precisely Engineered ADCs

Apr 16, 2018 6:30 am EDT

Sutro ADC Effectively Targets Folate Receptor Alpha in Ovarian Cancer Preclinical Research

Dec 12, 2017 8:00 am EST

Sutro Antibody Effectively Targets CD74 in Lymphoma & Multiple Myeloma Preclinical Studies

Oct 11, 2017 8:00 am EDT

Sutro Marks Two Drug Development Milestones